Replies to post #70694 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Improved dosing schedule and decreased quantity per injection. -- the latter increasing dc migration.....in theory, but you knew that.

Even Dr. Bosch himself was pleasantly surprised at the apparent significant responses in the double rapid progressors and indeterminates, since they otherwise left these patients out of the phase III trial because researchers originally assumed they would not be significantly helped.

Ok, back to waiting for results in the phase iii trial.

[Rkmatters]

To quote the Germans on Phase III:

"Determined at or prior to Baseline:

- Patients who have evidence of disease progression (including possible Pseudoprogression) as determined by central review"

https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001977-13/DE

More proof that the study removes psPDs whose condition shows up by baseline, and that means there "apparently" are psPDs in the Compassionate Use Arm data. Anyone who states there is not is spreading lies.

[Do Due Dilligence]

Most of them are true ePD, they confirmed only 1 psPD while they confirmed 20 ePD, there you have your probable ratio of psPD in indeterminate pool.
I would like to believe that he (they) lived at least 4 years but it is not guaranteed.

The 20 confirmed ePD have a median OS of 15 months, 50% better than historical controls. Even if these are good numbers, I didn't include them as trial is for ndGBM and I guess that if they do a rGBM trial it will be in combo with anti PD-L1.

[Do Due Dilligence]

There it is.